Preventing infections caused by the Ehrlichia chaffeensis bacterium
Keys to prevent iron hijacking and infection by intracellular bacteria
This study is looking at how a germ that causes a type of infection called human monocytic ehrlichiosis (HME) survives in our bodies, and it’s testing a special treatment that might stop the germ from getting the iron it needs to grow, which could help in finding new ways to prevent or treat this infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10762967 on NIH RePORTER |
What this research studies
This research focuses on understanding how the bacterium Ehrlichia chaffeensis, which causes human monocytic ehrlichiosis (HME), survives and infects human cells. The researchers aim to identify ways to block the bacterium's ability to acquire iron from host cells, which is crucial for its growth. By using an iron chelator called deferoxamine, they have found that they can completely prevent the infection in human macrophages. The study will explore the mechanisms involved in this process, potentially leading to new strategies for preventing or treating HME.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of or diagnosed with human monocytic ehrlichiosis, particularly those exposed to ticks.
Not a fit: Patients who are not at risk of tick exposure or do not have a diagnosis related to Ehrlichia chaffeensis infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively prevent or limit infections caused by Ehrlichia chaffeensis.
How similar studies have performed: Previous research has shown promising results in using iron chelation to block bacterial infections, suggesting that this approach may be effective.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Rikihisa, Yasuko — Ohio State University
- Study coordinator: Rikihisa, Yasuko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.